Glauco Valdivieso-Jiménez, Dennis Anthony Pino-Zavaleta, Susan K Campos-Rodriguez, Brando Ortiz-Saavedra, María F Fernández, Vicente Aleixandre Benites-Zapata
Aripiprazole is an atypical antipsychotic medication, and its use in treating borderline personality disorder (BPD) is debatable because it is not FDA-approved for treating BPD. This study aimed to investigate the efficacy and safety of aripiprazole in patients with BPD. On July 2, 2021, the protocol (CRD42021256647) was registered in PROSPERO. PubMed, Scopus, Web of Science, Ovid-Medline, Embase, PsycINFO, and Cochrane (CENTRAL) were searched without regard for language or publication date. We also searched trial registries on ClinicalTrials...
August 11, 2023: Psychiatric Quarterly